These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30358113)

  • 21. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
    Kim E; Seftel A; Goldfischer E; Baygani S; Burns P
    Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erectile dysfunction and the drugs to treat it. In many cases, medications are all a man needs to stay sexually active.
    Harv Health Lett; 2014 May; 39(7):7. PubMed ID: 25073193
    [No Abstract]   [Full Text] [Related]  

  • 23. [Determination of apomorphine, sildenafil and alprostadil in medicines for erectile dysfunction by high performance liquid chromatography-mass spectrometry].
    Xu Y; Xu G
    Se Pu; 2005 Nov; 23(6):633-5. PubMed ID: 16498994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction.
    Jannini EA; Isidori AM; Gravina GL; Aversa A; Balercia G; Bocchio M; Boscaro M; Carani C; Corona G; Fabbri A; Foresta C; Forti G; Francavilla S; Granata AR; Maggi M; Mansani R; Palego P; Spera G; Vetri M; Lenzi A;
    J Sex Med; 2009 Sep; 6(9):2547-60. PubMed ID: 19570039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors.
    Tolrà JR; Campaña JMC; Ciutat LF; Miranda EF
    J Sex Med; 2006 Sep; 3(5):901-909. PubMed ID: 16942534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. UHPLC for quality evaluation of genuine and illegal medicines containing sildenafil citrate and tadalafil.
    Reis NFA; Silva LFG; Souza MACE; Fialho SL; Souza Moreira CP; Oliveira Andrade MV; Paula WX; Gloria MBA; Pianetti GA; Fernandes C
    J Chromatogr Sci; 2021 Jan; 59(1):30-39. PubMed ID: 33107906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Rapid screening and confirmation of illegally added anti- impotence preparations in health care products by high performance liquid chromatography-high resolution mass spectrometry].
    Hu T; Qu X; Kang M; Song Q; Yang L; Zhao Y; Zhang D
    Se Pu; 2015 Aug; 33(8):897-901. PubMed ID: 26749869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
    Hsu JC; Tang DH; Lu CY
    Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three-dimensional models of Mycobacterium tuberculosis proteins Rv1555, Rv1554 and their docking analyses with sildenafil, tadalafil, vardenafil drugs, suggest interference with quinol binding likely to affect protein's function.
    Dash P; Bala Divya M; Guruprasad L; Guruprasad K
    BMC Struct Biol; 2018 Apr; 18(1):5. PubMed ID: 29669541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
    Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC
    Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
    Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
    J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction.
    Kotera J; Mochida H; Inoue H; Noto T; Fujishige K; Sasaki T; Kobayashi T; Kojima K; Yee S; Yamada Y; Kikkawa K; Omori K
    J Urol; 2012 Aug; 188(2):668-74. PubMed ID: 22704456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
    Mostafa T
    Sex Med Rev; 2016 Jul; 4(3):270-284. PubMed ID: 27871960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of synthetic phosphodiesterase-5 inhibitors by LC-MS
    Campillo N; Marín J; Fenoll J; Garrido I; López-García I; Hernández-Córdoba M; Viñas P
    Talanta; 2017 Nov; 174():638-644. PubMed ID: 28738634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening sexual performance enhancing compounds and their analogues in counterfeit and illicit erectile dysfunction drugs by high-performance liquid chromatography and liquid chromatography-tandem mass spectrometry.
    Lee JH; Han JH; Kim S; Kim NS; Yoon CY; Kim J; Baek SY
    J Forensic Leg Med; 2021 Aug; 82():102224. PubMed ID: 34371245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the effects of systemic sildenafil, tadalafil, and vardenafil treatments on skin flap survival in rats.
    Kaya B; Çerkez C; Işılgan SE; Göktürk H; Yığman Z; Serel S; Can B; Ergün H
    J Plast Surg Hand Surg; 2015; 49(6):358-62. PubMed ID: 26107909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of an LC-ESI-MS/MS method for the quantitation of phosphodiesterase-5 inhibitors and their main metabolites in rat serum and brain tissue samples.
    Unceta N; Echeazarra L; Montaña M; Sallés J; Gómez-Caballero A; Goicolea MA; Barrio RJ
    J Pharm Biomed Anal; 2012 Nov; 70():529-33. PubMed ID: 22647499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of vardenafil and its major metabolite, N-desethylvardenafil, in human plasma: application to a pharmacokinetic study.
    Ku HY; Shon JH; Liu KH; Shin JG; Bae SK
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jan; 877(1-2):95-100. PubMed ID: 19042162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
    Cui Y; Liu X; Shi L; Gao Z
    Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of counterfeit medicines for erectile dysfunction from an illegal supply chain.
    Tomić S; Milcić N; Sokolić M; Martinac AI
    Arh Hig Rada Toksikol; 2010 Mar; 61(1):69-75. PubMed ID: 20338870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.